Tag: Microvention
Microvention officially rebrands to Terumo Neuro, reflecting “expanded focus and strategic...
Microvention, a wholly owned subsidiary of Terumo Corporation, has today announced its official rebranding to Terumo Neuro, effective immediately.
This name change signifies a new...
Microvention announces publication of one-year results from CLEVER study
Microvention, a wholly owned subsidiary of Terumo Corporation, has announced the recent publication in the Journal of NeuroInterventional Surgery (JNIS) of one-year results from...
Microvention announces publication of SOFAST clinical data
Microvention, a wholly owned subsidiary of Terumo Corporation, has today announced the publication of data from SOFAST—a prospective, multicentre US study assessing the efficacy...
Microvention announces US availability of LVIS EVO intraluminal support device
Microvention, a wholly owned subsidiary of Terumo Corporation, announced today that the LVIS EVO intraluminal support device is now commercially available for the treatment...
New SOFAST data show high technical success and first-pass rates with...
Fresh data from the SOFAST study have indicated high rates of technical success and first-pass reperfusion with the Sofia 6Fr Flow Plus aspiration catheter...
Microvention celebrates 10 years and more than 500,000 procedures with Sofia...
Microvention, a wholly owned subsidiary of Terumo Corporation, is celebrating a decade of legacy innovation commemorating the anniversary of its Sofia and Sofia Flow...
Microvention enters transradial access market with US FDA clearance of Sofia...
Microvention, a wholly owned subsidiary of Terumo Corporation, announced today that the Sofia EX 5Fr 115cm intracranial support catheter received US Food and Drug...
Microvention announces five-year WEB-IT data alongside two new device sizes
Microvention, a wholly owned subsidiary of Terumo Corporation, has announced the publication of five-year follow-up data from the WEB-IT trial and the addition of two...
Microvention announces commercial availability of ERIC retrieval device in the USA
Microvention, a wholly owned subsidiary of Terumo, has announced that the ERIC retrieval device is now commercially available in the USA for ischaemic stroke treatment, having...
WEB 17 device maintains efficacy, safety across ruptured and unruptured aneurysms
The Woven EndoBridge (WEB) 17 device (Microvention/Terumo Corporation) has demonstrated positive efficacy and safety outcomes in the prospective, multicentre CLEVER study, indicating its utility...
How do we improve the treatment of stroke patients in the...
This educational supplement has been sponsored by MicroVention.
Since its inception in 1997, MicroVention has gradually expanded its offerings from cerebral aneurysms to include several...
Microvention celebrates 25 years in neuroendovascular technologies with ‘Patient’s Day’
Microvention, a wholly owned subsidiary of Terumo Corporation, today celebrated its 25-year anniversary in the neuroendovascular technologies industry.
The capstone of Microvention’s 25th anniversary celebration...
SNIS 2022: WEB flow diverter shown to be safe and effective...
The Society of NeuroInterventional Surgery’s (SNIS) 19th annual meeting (25–29 July 2022, Toronto, Canada) saw research involving the Woven EndoBridge (WEB; Microvention/Terumo) device disclosed for the...
Multicentre study indicates WEB flow disrupters can safely be used in...
As per the findings of a multicentre, retrospective study, use indications for the Woven EndoBridge (WEB) intrasaccular flow disruption device (Microvention/Terumo) can be safely...
Microvention announces enrolment of first patient in STRAIT study evaluating new...
Microvention, a wholly owned subsidiary of Terumo Corporation, has announced the successful completion of its first patient enrolment in a multicentre, prospective, observational study...
Microvention announces treatment of first US patient with FRED X flow...
Microvention, a subsidiary of Terumo, has announced the first US clinical case using its next-generation flow diverter, the FRED X device, at Thomas Jefferson University Hospital...
“Welcome and exciting”: Evidence mounts in favour of flow diversion technologies
Multiple pieces of clinical research supporting the use of flow diverter devices to treat intracranial aneurysms have come to light so far in 2021....
FRED flow diverter safe and effective in treatment of “appropriately selected”...
The Flow Redirection Endoluminal Device stent system (FRED; MicroVention)—a flow diverter used to treat intracranial aneurysms—has been deemed safe and effective for this indication,...
MicroVention’s FRED flow diverter now FDA approved
MicroVention, a US based subsidiary of Terumo and a global neurovascular company announced the US FDA premarket approval (PMA) for the FRED (Flow re-direction...
Intrasaccular aneurysm treatment device receives US FDA PMA approval
MicroVention, a US-based subsidiary of Terumo and a global neurovascular company, announces the US FDA premarket approval (PMA) for the WEB aneurysm embolisation system...
Type of stent denotes degree of complete occlusion following stent-assisted coiling...
A study comparing three different stents used during stent-assisted coiling of cerebral aneurysms revealed that the type of stent used affects a patient’s immediate...
The WEB-IT trial: Positive safety and effectiveness results announced
MicroVention has announced the publication of the WEB-IT pivotal trial results in the online edition of the Journal of NeuroInterventional Surgery.
The WEB aneurysm embolisation system...
Novel intrasaccular aneurysm treatment device receives FDA PMA approval
MicroVention has announced that the FDA premarket approval (PMA) for the WEB Aneurysm Embolization System for the treatment of intracranial wide neck bifurcation aneurysms....
Wide neck bifurcation aneurysms treated safely in WEB trial
The treatment of wide neck bifurcation aneurysms is more incomplete and dangerous than you think, says Adam Arthur (professor of Neurosurgery, University of Tennessee...
Aneurysms treated with hydrogel coils have a significantly reduced recurrence rate...
The use of bare platinum coils resulted in aneurysm recurrence in 15.4% of cases compared to just 4.4% (p>0.001) when hydrogel coils were used....
Greater obliteration and less in-stent stenosis after ATLAS stent coiling as...
According to research published in the Journal of NeuroIntervential Surgery, Atlas stent-assisted coiling outperformed LVIS Jr in terms of greater obliteration rates and lower...
FDA clearance for SOFIA thrombectomy device
MicroVention has announced the US FDA clearance of a new clinical indication for the SOFIA Catheter (Soft TOrqueable catheter For Intracranial Access) to include...
MicroVention announces US FDA approval for neuro stent device
MicroVention has announced today the FDA Premarket Approval (PMA) for the LVIS and LVIS Jr. stents for stent-assisted coil embolisation of intracranial aneurysms. The LVIS and LVIS Jr....
Hydrogel coils beat bare platinum in comparison study
The GREAT randomised controlled trial has confirmed that better outcomes can be achieved with hydrogel coils compared to bare platinum coils for the treatment...
